Why Is Purple Biotech Stock Gaining Wednesday? - Purple Biotech (NASDAQ:PPBT)

Purple Biotech (NASDAQ/TASE: PPBT) reported Q2 2026 results and new preclinical data on its IM1240 tri-specific antibody. The company said IM1240 showed an 8-fold longer half-life and 16-fold higher exposure versus a non-capped variant, with reduced cytokines in toxicology work. Cash was $6.1 million at June 30, 2026, funding a runway to mid-2027. IM1240 is planned for clinical entry in 2027.

PURPLE BIOTECH LTD. (PPBT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Purple Biotech Reports Second Quarter 2026 Financial Results New preclinical data presented at European Association for Cancer Research (EACR) 2026 Annual Congress, which further validates the differentiated profile of IM1240’s anti-tumor activity, favorable safety a

Purple Biotech presented preclinical EACR 2026 data on its CAPTN-3 program, IM1240. A non-GLP NHP toxicology study validated the CAPTN-3 masking strategy, reporting ~8-fold longer half-life and 16-fold higher exposure versus the non-capped variant IM1222, with markedly lower cytokine release. In patient-derived PD-1/chemo-resistant tumor samples, IM1240 showed anti-tumor activity requiring CD3 and NKG2A, and in NSCLC explants induced mature tertiary lymphoid structures. The company plans first-i

Viking Therapeutics' stock rose 40% premarket after trial data showed its obesity drug VK2735 maintained weight loss with less frequent dosing. Patients kept 97% of weight loss on biweekly dosing and 90% on monthly dosing. Analysts highlight potential clinical advantages. The company aims to compete with Novo Nordisk and Eli Lilly in a market projected to reach $100B by 2030.

Rush Street Interactive (RSI) stock rose 4.8% in pre-market trading after Stifel initiated coverage with a Buy rating and $34 price target, citing its unique position in the U.S. iCasino market. Citizens reiterated its Market Outperform rating and $34 target, highlighting RSI's strong revenue growth, debt-free balance sheet, and undervaluation. The broader market showed modest gains, with RSI's surge driven by company-specific catalysts.

Wall Street analysts are optimistic about Meta Platforms' new AI agent, Muse, expecting it to generate significant revenue. Since its launch, Meta's shares have surged over 20%, adding $200 billion in market cap. Muse has seen 2.8 million downloads in 12 days, with analysts noting its potential for broad adoption and monetization. Brokerages like J.P. Morgan and BofA highlight Muse's strong product-market fit and early traction. Meta's stock has a median price target of $760 among 64 brokerages.